Burton's Agammaglobulinemia and COVID-19.
agammaglobulinemia
convalescent plasma
covid-19
immunodeficiency
ivig
sars-cov-2
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
25 Nov 2020
25 Nov 2020
Historique:
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
5
1
2021
Statut:
epublish
Résumé
During the SARS-CoV-2 global pandemic, many patients who have co-morbid conditions are considered high risk for morbidity and mortality; however, those who are immunodeficient are at higher risk of becoming seriously ill. In this article, we present a 26-year old male with a history of X-linked agammaglobulinemia who presented to the hospital with fever and chills after exposure to a SARS-CoV-2 positive individual. The patient had a prolonged course in the hospital, but his symptoms improved quickly after receiving convalescent plasma. This case highlights the clinical course of a patient with severe immunoglobulin deficiency and a possible treatment approach for patients with concomitant agammaglobulinemia and COVID-19.
Identifiants
pubmed: 33391934
doi: 10.7759/cureus.11701
pmc: PMC7769814
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e11701Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020, Hovey et al.
Déclaration de conflit d'intérêts
The authors have declared financial relationships, which are detailed in the next section.
Références
Pediatr Allergy Immunol. 2020 Jul;31(5):565-569
pubmed: 32319118
Cell. 1993 Jan 29;72(2):279-90
pubmed: 8425221
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4585-4596
pubmed: 32373999
Nature. 1993 Jan 21;361(6409):226-33
pubmed: 8380905
Medicine (Baltimore). 1996 Nov;75(6):287-99
pubmed: 8982147
BMC Med. 2020 Sep 3;18(1):270
pubmed: 32878619
Clin Rev Allergy Immunol. 2000 Oct;19(2):183-204
pubmed: 11107501
Medicine (Baltimore). 2006 Jul;85(4):193-202
pubmed: 16862044